<DOC>
	<DOCNO>NCT00099255</DOCNO>
	<brief_summary>This multi-center , phase II study conduct define toxicity profile antitumor activity SGN-30 patient pcALCL closely related lymphoproliferative disorder .</brief_summary>
	<brief_title>Study SGN-30 ( Anti-CD30 mAb ) Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Lymphoma , Primary Cutaneous Anaplastic Large Cell</mesh_term>
	<mesh_term>Lymphomatoid Papulosis</mesh_term>
	<criteria>Inclusion Criteria Patients must definite diagnosis . Patients must histologically confirm CD30 positive within 3 month enrollment Patients pcALCL must target lesion present least 1 month without spontaneous regression pcALCL patient must fail treatment local radiation therapy , fail systemic therapy single agent Patients must consider eligible candidate systemic therapy determine investigator All patient must three week washout previous treatment , unless opinion investigator best interest patient , point individual case must discuss medical monitor prior enrollment . Patients must ECOG performance status &lt; 2 ( Appendix B ) life expectancy &gt; six month . Patients must least 18 year age . Patients must available periodic blood sampling , studyrelated assessment , management toxicity treat institution . Females childbearing potential must negative HCG pregnancy test result within three day enrollment . All patient must agree use effective contraceptive method course study . Patients must give write informed consent . Required baseline laboratory data : Absolute neutrophil count great equal 1,000/mm3 , Platelet count great equal 75,000/mm3 , Serum bilirubin less equal 1.5 time ULN , Serum creatinine less equal 1.5 time ULN , BUN le equal 1.5 time ULN , SGOT le equal 2.5 ULN , SGPT le equal 2.5 ULN Criteria Exclusion Patients Sezary syndrome , type lymphoproliferative disease pcALCL , TMF LyP Patients systemic ALCL extracutaneous involvement cutaneous ALCL Patients know active systemic viral , bacterial , fungal infection Patients know HIV , Hepatitis B , Hepatitis C positive Patients treat previously antiCD30 antibody Patients know hypersensitivity recombinant proteins excipient contain drug formulation Patients history malignancy past five year exception adequately treat basal squamous cell skin cancer cervical carcinoma situ Patients symptomatic cardiac disease include ventricular dysfunction , coronary artery disease , arrhythmias Patients pregnant breastfeeding Patients serious underlying medical condition would impair ability receive tolerate plan treatment Patients dementia alter mental status would preclude understand render informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Keyword ?</keyword>
	<keyword>Primary Cutaneous Anaplastic Large Cell Lymphoma</keyword>
	<keyword>Large Cell Transformation Mycosis Fungoides</keyword>
	<keyword>Lymphomatoid Papulosis</keyword>
</DOC>